Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Protagonist Therapeutics, Inc is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Protagonist Therapeutics employs 76 staff and has a trailing 12-month revenue of around USD$25.7 million.
|52-week range||USD$5.3 - USD$31.5|
|50-day moving average||USD$23.9032|
|200-day moving average||USD$21.8826|
|Wall St. target price||USD$33.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.742|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$25.7 million|
|Gross profit TTM||USD$231,000|
|Return on assets TTM||-21.17%|
|Return on equity TTM||-48.89%|
|Market capitalisation||USD$1.3 billion|
TTM: trailing 12 months
There are currently 2.8 million Protagonist Therapeutics shares held short by investors – that's known as Protagonist Therapeutics's "short interest". This figure is 1.8% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting Protagonist Therapeutics shares can be evaluated.
Protagonist Therapeutics's "short interest ratio" (SIR) is the quantity of Protagonist Therapeutics shares currently shorted divided by the average quantity of Protagonist Therapeutics shares traded daily (recently around 353777.76365947). Protagonist Therapeutics's SIR currently stands at 7.87. In other words for every 100,000 Protagonist Therapeutics shares traded daily on the market, roughly 7870 shares are currently held short.
However Protagonist Therapeutics's short interest can also be evaluated against the total number of Protagonist Therapeutics shares, or, against the total number of tradable Protagonist Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Protagonist Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Protagonist Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0725% of the tradable shares (for every 100,000 tradable Protagonist Therapeutics shares, roughly 73 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Protagonist Therapeutics.
Find out more about how you can short Protagonist Therapeutics stock.
We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $5.3 up to $31.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 1.54. This would suggest that Protagonist Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.